Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Antigen epitope peptide and application thereof

An antigen epitope and antigen technology, applied in the field of molecular immunology, can solve the problem of insufficient immunogenicity of tumor-specific antigens

Inactive Publication Date: 2017-02-15
XIN HUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
View PDF1 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] In view of the problems of insufficient immunogenicity of tumor-specific antigens in the prior art, the present invention provides an antigenic epitope peptide and its application

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antigen epitope peptide and application thereof
  • Antigen epitope peptide and application thereof
  • Antigen epitope peptide and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0046] Example 1: Prediction and synthesis of HLA-A0201-restricted LMP1 protein CTL epitope peptide

[0047] (1) Determination of the amino acid sequence of LMP1 protein:

[0048] By searching the LMP1 protein sequence in the Genbank database and using the sequence set with the Genbank accession number: AAS99612.1, an LMP1 protein sequence was obtained, which consists of 382 amino acid residues, as shown in SEQ ID No.1.

[0049] (2) Online prediction of LMP1 protein epitope peptide:

[0050] Using the Epitope Peptide Prediction Database

[0051] a: https: / / www-bimas.cit.nih.gov / cgi-bin / molbio / ken_parker_comboform and

[0052] b: http: / / www.syfpeithi.de / bin / MHCServer.dll / EpitopePrediction.htm)

[0053] The service provided is to make a preliminary prediction of the HLA-A0201-restricted LMP1 protein epitope peptide, select several epitope peptides with the highest scores, and then use the supermotif and quantitative motif scheme to modify the initially predicted CTL epitope pep...

Embodiment 2

[0063] Example 2: T2 cell epitope peptide binding affinity and stability experiments

[0064] The affinity and stability of HLA-A0201 and peptides were determined with the help of the characteristics of T2 cells.

[0065] (1) T2 cell affinity experiment

[0066] Collect T2 cells, centrifuge and wash three times with sterile PBS at 4°C, add serum-free 1640 medium, 2×10 5 Cells per well were seeded in a 24-well cell culture plate, and an experimental group and a control group were set up. Three secondary wells were repeated for each group. T2 cells stimulated without peptides were used as blank controls, and corresponding experimental peptides (aa32 and aa167) and control peptide (positive control: HIVpol peptide; negative control: influenza virus matrix protein peptide FLU-matrix) (final concentration 50uM), while adding β2 microglobulin (final concentration 2.5ug / ml). Place cells at 37 °C, 5% CO 2 Incubate in the incubator for 18 hours, collect the cells again, wash three t...

Embodiment 3

[0073] Example 3: Detection of pentamer-positive cytotoxic T cells corresponding to peptides aa32 and aa167

[0074] The corresponding pentamers of peptides aa32 and aa167 are based on the principle of dual recognition of T cell activation, using bioengineering technology to assemble MHC class I molecule heavy chain α and β2 microglobulin in vitro, and combine with antigenic epitope peptides to form a The monomers corresponding to TCR specific binding, and then five monomers are assembled together to form a pentamer.

[0075] A healthy donor and seven patients were selected to detect CD8 positive for LMP1 epitope peptide pentamer in their peripheral blood + number of cells. Collect 5ml of peripheral blood from healthy donors and patients diagnosed with lymphoma without remission, extract peripheral blood mononuclear cells with lymphocyte separation medium, count the cells and take 1×10 6 Dissolve in 100ul PBS, add 2ul PE-labeled pentamer corresponding to peptide aa32 or aa16...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an antigen epitope peptide. Amino acid sequences of the antigen epitope peptide contain an amino acid sequence shown as SEQ ID NO.2 or SEQ ID NO.3, or an amino acid sequence formed by adding one or more amino acids to the amino acid sequence shown as SEQ ID NO.2 or SEQ ID NO.3, deleting one or more amino acids from the amino acid sequence shown as SEQ ID NO.2 or SEQ ID NO.3 or substituting one or more amino acids. The antigen epitope peptide can be used for producing antigen-presenting cells, major histocompatibility antigen complexes or cytotoxic T lymphocyte inducers, and can be further used for preparing drugs for treating cancer such as NK / T-cell lymphoma.

Description

technical field [0001] The invention belongs to the field of molecular immunology and relates to antigenic epitope peptides, in particular to epitope peptides recognized by HLA-A0201-restricted cytotoxic T lymphocytes (CTL) and applications thereof. Background technique [0002] NK / T cell lymphoma is a malignant tumor of the hematological system. The incidence rate in the United States is not high, but in Asia, especially East Asia, its incidence rate is significantly higher than that in Europe and the United States. The primary site of NK / T cell lymphoma is mostly the nasopharynx. After receiving combined radiotherapy and chemotherapy and autologous peripheral blood hematopoietic stem cell transplantation, some patients can be cured, but many patients will eventually relapse. At present, it is believed that the root cause of the recurrence of these patients is the existence of minimal residual lesions in the body. Therefore, an effective method is needed to effectively elim...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K14/705C07K14/74C12N15/12C12N5/078C12N5/0783A61K39/00A61P35/00
CPCC07K14/705A61K39/0005C12N5/0634C12N5/0638C12N2501/998
Inventor 陶荣郝思国张文皓
Owner XIN HUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com